Literature DB >> 15194585

Autoantibodies against granulocyte-macrophage colony stimulating factor and interleukin-3 are rare in patients with Felty's syndrome.

B Hellmich1, A Ciaglo, H Schatz, G Coakley.   

Abstract

OBJECTIVES: Antibodies against granulocyte colony stimulating factor are frequently found in patients with Felty's syndrome (FS). In this study, we examined the prevalence of antibodies against two other granulopoietic cytokines: granulocyte-macrophage colony stimulating factor (GM-CSF) and interleukin-3 (IL3).
METHODS: Sera of 32 patients with FS, 20 normocytic patients with rheumatoid arthritis (RA), and 72 healthy individuals were screened for the presence of antibodies against GM-CSF and IL3 by ELISA and bioassays, using the human erythroleukaemia cell line TF-1.
RESULTS: In two of the 32 patients with FS, antibodies to GM-CSF and IL3 were detectable by ELISA. Binding anti-GM-CSF antibodies were also detected in one of the 72 healthy controls, while in another healthy subject and in one of the patients with normocytic RA, anti-IL3 antibodies were present. Serum from one of the two patients with FS who tested positive for anti-IL3 and anti-GM-CSF antibodies by ELISA showed strong neutralising capacity to the biological effect of IL3, but not to GM-CSF in vitro. Patients with FS had significantly higher serum levels of GM-CSF (median; 2.82 pg/mL; interquartile range 2.64-3.19 pg/mL) compared with patients with RA (2.52 pg/mL; 2.28-2.72 pg/mL; p = 0.012) and healthy controls (2.23 pg/mL; 2.04-2.52; p<0.001). In addition, serum levels of IL3 in patients were significantly higher in FS (10.05 pg/mL; 8.94-11.98) compared with controls (4.79 pg/mL; 3.72-7.22; p<0.001), but not compared with RA patients (9.52 pg/mL; 8.32-10.42; p = 0.17).
CONCLUSIONS: Antibodies to GM-CSF and IL3 are rare in patients with FS and RA and in healthy subjects. In individual patients with FS, the presence of neutralising anti-IL3 antibodies may contribute to the development of cytopenia.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194585      PMCID: PMC1755075          DOI: 10.1136/ard.2003.011056

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  26 in total

Review 1.  Specificity in cytokine signal transduction: lessons learned from the IL-3/IL-5/GM-CSF receptor family.

Authors:  N Geijsen; L Koenderman; P J Coffer
Journal:  Cytokine Growth Factor Rev       Date:  2001-03       Impact factor: 7.638

2.  Polymorphonuclear leukocyte inclusions and impaired bacterial killing in patients with Felty's syndrome.

Authors:  R C Gupta; F M Laforce; D M Mills
Journal:  J Lab Clin Med       Date:  1976-08

3.  Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin.

Authors:  Nicole Casadevall; Joelle Nataf; Beatrice Viron; Amir Kolta; Jean-Jacques Kiladjian; Philippe Martin-Dupont; Patrick Michaud; Thomas Papo; Valerie Ugo; Irene Teyssandier; Bruno Varet; Patrick Mayeux
Journal:  N Engl J Med       Date:  2002-02-14       Impact factor: 91.245

4.  Spontaneously occurring neutralizing antibodies against granulocyte-macrophage colony-stimulating factor in patients with autoimmune disease.

Authors:  A Meager; M Wadhwa; C Bird; P Dilger; R Thorpe; J Newsom-Davis; N Willcox
Journal:  Immunology       Date:  1999-07       Impact factor: 7.397

5.  Major histocompatility complex haplotypic associations in Felty's syndrome and large granular lymphocyte syndrome are secondary to allelic association with HLA-DRB1 *0401.

Authors:  G Coakley; D Brooks; M Iqbal; E Kondeatis; R Vaughan; T P Loughran; G S Panayi; J S Lanchbury
Journal:  Rheumatology (Oxford)       Date:  2000-04       Impact factor: 7.580

6.  Inhibition of human bone marrow-granulocyte precursors by serum from patients with Felty's syndrome.

Authors:  L S Goldberg; P A Bacon; R C Bucknall; J Fitchen; M J Cline
Journal:  J Rheumatol       Date:  1980 May-Jun       Impact factor: 4.666

7.  Low Fcgamma receptor III and high granulocyte colony-stimulating factor serum levels correlate with the risk of infection in neutropenia due to Felty's syndrome or systemic lupus erythematosus.

Authors:  Bernhard Hellmich; Elena Csernok; Masja de Haas; Albert E G K R von dem Borne; Helmut Schatz; Wolfgang L Gross; Armin Schnabel
Journal:  Am J Med       Date:  2002-08-01       Impact factor: 4.965

8.  Autoantibodies against granulocyte colony-stimulating factor in Felty's syndrome and neutropenic systemic lupus erythematosus.

Authors:  Bernhard Hellmich; Elena Csernok; Helmut Schatz; Wolfgang L Gross; Armin Schnabel
Journal:  Arthritis Rheum       Date:  2002-09

9.  Humoral and cellular immune mechanisms of neutropenia in patients with Felty's syndrome.

Authors:  G Starkebaum; J W Singer; W P Arend
Journal:  Clin Exp Immunol       Date:  1980-02       Impact factor: 4.330

10.  Idiopathic pulmonary alveolar proteinosis as an autoimmune disease with neutralizing antibody against granulocyte/macrophage colony-stimulating factor.

Authors:  T Kitamura; N Tanaka; J Watanabe; S Kanegasaki; Y Yamada; K Nakata
Journal:  J Exp Med       Date:  1999-09-20       Impact factor: 14.307

View more
  3 in total

Review 1.  [Early diagnosis of chronic systemic inflammatory disorders].

Authors:  B Hellmich; F Merkel; M Weber; W L Gross
Journal:  Internist (Berl)       Date:  2005-04       Impact factor: 0.743

2.  Anti-cytokine autoantibodies in autoimmune diseases.

Authors:  Giuseppe Cappellano; Elisabetta Orilieri; Abiy D Woldetsadik; Elena Boggio; Maria F Soluri; Cristoforo Comi; Daniele Sblattero; Annalisa Chiocchetti; Umberto Dianzani
Journal:  Am J Clin Exp Immunol       Date:  2012-11-15

Review 3.  Neutropenia in the Elderly: A Rheumatology Perspective.

Authors:  Su-Ann Yeoh; Christine Fox; Richard Hull
Journal:  Drugs Aging       Date:  2016-08       Impact factor: 3.923

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.